

# Clarity on Mergers & Acquisitions

Your annual Swiss M&A recap and outlook

January 2026

## 01 Editorial

## 02 Facts & Figures

## 04 Sector Reports

- 05 Chemicals
- 06 Commodities
- 07 Consumer Markets
- 08 Financial Services
- 09 Industrial Markets
- 10 Pharmaceuticals & Life Sciences
- 11 Power & Utilities
- 12 Private Equity
- 13 Real Estate
- 14 Technology, Media & Telecommunications

## 15 Credentials

## 21 Methodology



Photo by Daniel Hager

## Decisive deals in uncertain times

Despite ongoing economic uncertainty in 2025, Swiss dealmakers continued to move in the M&A market. Activity went a step further than in the prior year, and yet, the year carried a tension many of us felt in real time. Even with stronger headline figures, 2025 still landed slightly below what many market participants had expected. This combination says something important about today's market: confidence is returning in pockets, but discipline remains the defining trait.

With the prospect of "perfect" conditions a distant memory, dealmakers are no longer waiting for clarity; they are adapting. Swiss companies remained active participants in cross-border transactions, most notably as buyers. Nearly half of all deals involved Swiss acquirers purchasing abroad, while inbound acquisitions of Swiss targets represented roughly a quarter of transactions. This international footprint brings opportunity, but it also raises the bar for execution. Differences in legal systems, accounting frameworks, and deal cultures require more than technical alignment. They demand a shared understanding of risk, value, and expectations. In our experience, the transactions that work best are those that build a shared understanding early and translate it into clear, workable agreements.

**Timo Knak**

Partner, Deal Advisory, Head Deal Advisory and Head of Mergers & Acquisitions

This demanding execution environment is also evident in the distribution of deal activity across the Swiss market mix. Technology, Media & Telecommunications (TMT) led activity by deal count, while Pharmaceuticals & Life Sciences drove value, reflecting where capital continues to concentrate. At the same time, deal volume remained shaped by a handful of outsized transactions, led by Holcim's spin-off of Amrize. When large deals carry that much weight, it is easy to misread the market. The more useful question is: what lies beneath the headlines? Which themes are consistently driving decisions, and where are risks becoming more material?

Looking ahead to 2026, we anticipate a moderate increase in M&A activity, supported by a slightly higher share of Private Equity-backed transactions. But the more decisive shift is qualitative. AI capability, cyber resilience, and enterprise-wide readiness are becoming central to how value is underwritten and protected, not just topics for late-stage diligence. In a market where timelines are compressed and stakeholder scrutiny is high, readiness is increasingly what separates deals that close and integrate smoothly from those that stall or underperform.

Clarity on Mergers & Acquisitions 2025 reflects a market that is active, sophisticated, and outward-looking. We believe it also highlights a simple imperative for Swiss dealmakers: match strategic ambition with disciplined execution. Because value creation does not end at signing – it begins with it.

## Top 5 Swiss M&A deals 2025


1	2	3	4	5
<b>Target</b>	<b>Amrize Ltd *</b>	<b>Avidity Biosciences Inc</b>	<b>Baloise Holding Ltd **</b>	<b>Techem GmbH</b>
Announced date	Feb 2025	Oct 2025	Apr 2025	Jul 2025
Stake	100%	100%	100%	100%
Target country	Switzerland, USA	USA	Switzerland	Germany
Bidder	Public & Existing Shareholders	Novartis AG	Helvetia Holding AG	Consortium led by Partners Group Holding AG
Bidder country	Various	Switzerland	Switzerland	Switzerland
Seller	Holcim Ltd			Caisse de Depot et Placement du Quebec; Ontario Teachers Pension Plan; Partners Group Holding AG
Seller country	Switzerland			Canada; Canada; Switzerland
Value USD m	<b>33,738</b>	12,000	10,771	7,824
				5,375

\* Value equals total registered shares post IPO multiplied by the closing price of the first trading day plus net debt

\*\* Following the announcement of the merger between Helvetia Holding AG and Baloise Holding Ltd, Patria Genossenschaft acquired a 9.4% stake on 25 April 2025 in Baloise Holding Ltd from Cevian Capital, an activist investor in Baloise Holding Ltd, in a deal worth c. CHF 1 billion


## Number and value of deals

per year



## Number of deals

by deal size 2025 (with available deal value, in USD)



## Number of deals

by industry sector 2025



# Sector Reports

## Clarity on Mergers & Acquisitions

The Swiss M&A landscape:  
recap and outlook

# Chemicals



Deal count

9

Deal value in USD bn

1.6

## Breakdown by subindustry

% of deals, by number

44% Industrial Chems

33% Speciality Chems

22% Agrochems &amp; Seeds

## Top 1 Swiss Chemicals deal 2025

1

Target	DSM-Firmenich AG (Feed Enzyme Alliance)
Announced date	Feb 2025
Stake	50%
Target country	Netherlands
Bidder	Novozymes A/S
Bidder country	Denmark
Seller	DSM-Firmenich AG
Seller country	Switzerland, Netherlands
Value USD m	1,549

## 2025 review

Deal activity in the Swiss Chemicals sector increased modestly from 8 to 9 transactions. Total disclosed deal value was mainly driven by Novozymes' acquisition of DSM-Firmenich's remaining 50% stake in the Feed Enzyme Alliance, which clearly stood out as the only value-significant transaction. Most other transactions did not disclose financial terms, underlining the fragmented and selective nature of dealmaking in the sector.

Deal activity was somewhat evenly distributed across the three subsectors Industrial Chemicals, Agrochems & Seeds, and Specialty Chems. Inbound cross-border deals were limited, with no purely domestic Swiss transactions, highlighting the industry's strong focus on international markets.

For more information  
please contact:



**Peter Dauwalder**  
Partner, Deal Advisory,  
Head of Turnaround  
& Restructuring  
+41 58 249 41 80  
pdauwalder@kpmg.com



**Jan-Philipp Weber**  
Director, Deal Advisory,  
Turnaround & Restructuring  
+41 58 249 42 17  
jpweber@kpmg.com

## 2026 outlook

In 2026, the Chemicals sector is likely to stay cautious as overcapacity, weak demand, and regulation continue to limit investment and deal activity, with uneven momentum across regions. North America should see selective growth deals, Europe more divestments, while interest stays focused on more stable segments and Swiss M&A remains selective but steady.

# Commodities



Deal count

21

Deal value in USD bn

3.3

## Breakdown by subindustry

% of deals, by number

43% Energy

33% Metals

24% Agriculture

## Top 3 Swiss Commodities deals 2025

1	2	3
<b>Target</b>	<b>Congo LNG project; Oil &amp; Gas Assets (Baleine project)</b>	<b>SolGold plc</b>
Announced date	Mar 2025	Nov 2025
Stake	25%; 30%	88%
Target country	Côte d'Ivoire; Republic of the Congo	Switzerland, UK
Bidder	Vitol Netherlands Coooperatief UA	Jiangxi Copper Co Ltd
Bidder country	Switzerland, Netherlands	China
Seller	ENI SpA	The Aga Khan Development Network
Seller country	Italy	Switzerland
Value USD m	<b>1,650</b>	1,174
		206

## 2025 review

Commodity-sector deal activity remained resilient in 2025, with 21 transactions compared with 23 in 2024. Energy-related deals continued to dominate with nine deals, driven by acquisitions of midstream and downstream assets, while Metals accounted for seven transactions and Agriculture for five.

In 2025, the standout transaction in the Commodities sector was Vitol's acquisition from Eni of a 30% stake in the Baleine oil and gas project in Côte d'Ivoire, along with a 25% stake in the Congo LNG project in the Republic of the Congo, for a total consideration of USD 1.7 billion. This deal further strengthens the cooperation between the two companies in West Africa.

For more information  
please contact:



**Jean-Christophe Pesser**  
Partner, Deal Advisory,  
Head of Diligence Services  
+41 58 249 35 90  
jpesser@kpmg.com



**Antoine Chappuis**  
Director, Deal Advisory,  
Diligence Services  
+41 58 249 51 76  
achappuis@kpmg.com

## 2026 outlook

Strong M&A momentum is expected to continue in the Commodities sector in 2026, as key players leverage capital reserves accumulated in recent years to reshape their portfolios and capture growth opportunities. Consolidation and strategic repositioning are expected to continue shaping activity in the Energy and Metals segments, while the energy transition and the need to secure access to critical minerals will continue to define the dealmaking landscape.

# Consumer Markets



Deal count  
**54**

Deal value in USD bn  
**11.1**

## Breakdown by subindustry

% of deals, by number

37% Food

35% Retail

15% Other

9% Apparel

4% Luxury Goods

## Top 3 Swiss Consumer Markets deals 2025\*

1	2	3	
<b>Target</b>	<b>Cconomy AG</b>	<b>Coca-Cola Beverages Africa Pty Ltd</b>	<b>Carrefour Italia SpA</b>
Announced date	Jul 2025	Oct 2025	Jul 2025
Stake	100%	75%	100%
Target country	Germany	South Africa	Italy
Bidder	JD.com Inc; JINGDONG Holding Germany GmbH	Coca-Cola HBC AG	Newlat Food SpA; Newlat Group SA
Bidder country	China, Cayman Islands; Germany	Switzerland, Greece	Italy; Switzerland, Italy
Seller	Beisheim Holding AG; Various other German investors	Coca-Cola Co; Gutsche Family Investments	Carrefour SA
Seller country	Switzerland; Germany	USA; South Africa	France
Value USD m	<b>4,850</b>	3,670	1,176

\* The top three deals have limited exposure to Switzerland; however, they are included as they meet the established methodology criteria

## 2025 review

Deal activity in Consumer Markets rose from 45 to 54 transactions year-on-year, while total deal value expanded more significantly from USD 2.8 billion to roughly USD 11.1 billion, reflecting a clear shift toward larger assets and transactions. This trend mirrors the overall global pattern for the sector, with companies pivoting toward larger, more selective transactions with achievable synergies.

The standout deal was JD.com's USD 4.9 billion acquisition of Cconomy AG, supporting JD.com's strategy to build a leading omnichannel consumer electronics platform in Europe.

For more information  
please contact:



**Joshua Martin**  
Partner, Deal Advisory,  
Global Head of  
Transaction Services  
+41 58 249 35 76  
jmartin12@kpmg.com



**Johannes Post**  
Partner, Deal Advisory,  
Global Head of Valuations  
+41 58 249 35 92  
jpost@kpmg.com

## 2026 outlook

2026 is expected to be the year of the carve-outs, as companies look to address both dilutive non-core businesses and the increasing penalty that we see being placed on multi-category businesses. Together with strengthening Private Equity activity, we expect 2026 to continue the upward trend in activity established in 2025. This activity will focus on the Food sector, but we expect the Retail sector to be busy, driven by existential need for consolidation.

# Financial Services



Deal count

40

Deal value in USD bn

13.4

## Breakdown by subindustry

% of deals, by number

35% Investment Management

33% Insurance

25% Banking

8% Other

## Top 3 Swiss Financial Services deals 2025

1	2	3
<b>Target</b>	<b>Baloise Holding Ltd</b>	<b>Saxo Bank A/S</b>
Announced date	Apr 2025	Mar 2025
Stake	100%	70%
Target country	Switzerland	Denmark
Bidder	Helvetia Holding AG	Bank J Safra Sarasin Ltd
Bidder country	Switzerland	Switzerland
Seller		Zhejiang Geely Holding Group Co Ltd; Mandatum Pankki Oyj
Seller country		China; Finland
Value USD m	<b>10,771</b>	1,215
		321

## 2025 review

The Financial Services sector saw deal activity fall from 45 to 40 transactions, while total value rose to about USD 13.4 billion, compared to USD 2.1 billion last year, showing continued appetite for transformative deals. The leading transaction was the USD 10.8 billion merger of equals between Helvetia Holding and Baloise Holding, forming Helvetia Baloise Holding Ltd and establishing Switzerland's second-largest insurance group with c. CHF 20.0 billion in business volume.

For more information  
please contact:



### Christian Hintermann

Partner, Financial Services,  
Head of Financial Services  
Deal Advisory  
+41 58 249 29 83  
chintermann@kpmg.com



### Benedikt Kolling

Senior Manager,  
Financial Services  
+41 58 249 90 82  
benediktolling@kpmg.com

## 2026 outlook

Low rates will keep squeezing banks' net interest income, prolonging 2025's challenges and driving M&A among small and mid-sized banks. With wealth management margins under pressure, Independent Asset Management (IAM) consolidation is set to accelerate, increasingly led by Private Equity-backed players. Insurance brokerage deals should also rise in 2026, as new entrants, regulation, the UK/Swiss Financial Services Agreement, and increasing demands push small- and medium-sized brokers to consolidate. Selected insurer transactions are also likely, as firms seek scale and shared functions.

# Industrial Markets



Deal count

72

Deal value in USD bn

8.8

## Breakdown by subindustry

% of deals, by number

46% Industrial Products &amp; Services

26% Manufacturing &amp; Machinery

11% Electronics  
(industrial types such as robotics)

8% Automotives

6% Automation

3% Other

## Top 3 Swiss Industrial Markets deals 2025

	1	2	3
Target	<b>ABB Ltd</b> (Robotics division)	<b>Oerlikon Textile GmbH &amp; Co KG</b> ("Barmag")	<b>TT Electronics plc</b>
Announced date	Oct 2025	May 2025	Oct 2025
Stake	100%	100%	100%
Target country	Switzerland	Germany	United Kingdom
Bidder	SoftBank Group Corp	Rieter Holding AG	Cicor Technologies Ltd
Bidder country	Japan	Switzerland	Switzerland
Seller	ABB Ltd	OC Oerlikon Corp AG	Aberforth Partners LLP
Seller country	Switzerland	Switzerland	United Kingdom
Value USD m	<b>5,375</b>	1,153	496

## 2025 review

Swiss industrial M&A slowed, with deal volume falling from 84 to 72 and value dropping from USD 24.4 billion to USD 8.8 billion, reflecting fewer large deals. SoftBank's USD 5.4 billion purchase of ABB's robotics unit stood out, while small- and mid-cap activity stayed steady, supported by exposure to tariff risks.

Industrial Products & Services accounted for 46% of activity, followed by Manufacturing & Machinery at 26%, with other subsectors making up the balance. Deal flow was mainly cross-border, including 34 Swiss outbound, 21 inbound acquisitions, and 16 foreign-to-foreign deals with Swiss sellers, while Swiss-to-Swiss activity was limited to one transaction.

For more information  
please contact:



**Remo Huser**  
Partner, Deal Advisory,  
Mergers & Acquisitions  
+41 58 249 68 35  
rhuser@kpmg.com



**Stephan Grüber**  
Partner, Deal Advisory,  
Diligence Services  
+41 58 249 65 66  
sgrueber@kpmg.com

## 2026 outlook

Swiss industrial M&A is expected to recover in FY26, as clearer interest rate paths and tariff frameworks reduce uncertainty and allow companies to restart postponed transactions. Activity should remain selective, with firms pursuing focused acquisitions to build scale and capabilities while maintaining tight diligence on tariff exposure, sourcing risks, and supply-chain stability.

# Pharmaceuticals & Life Sciences



Deal count

74

Deal value in USD bn

53.0

## Breakdown by subindustry

% of deals, by number

35% Biotech

26% Medtech/Lab Equipment

18% Clinics/Healthcare

16% Pharma

5% Other

## Top 3 Swiss Pharmaceuticals & Life Sciences deals 2025

1	2	3
<b>Target</b>	<b>Avidity Biosciences Inc</b>	<b>Argo Biopharmaceutical Co Ltd *</b>
Announced date	Oct 2025	Sep 2025
Stake	100%	100%
Target country	USA	China
Bidder	Novartis AG	Novartis AG
Bidder country	Switzerland	Switzerland
Seller		Argo Biopharma Inc
Seller country		China
Value USD m	<b>12,000</b>	5,360
		5,250

\* License ex-China rights to two discovery-stage next-generation molecules, with reciprocal options to share in Profit & Loss in the U.S. and China for an additional hepatic-delivered siRNA candidate

\*\* Petrelintide monotherapy development and commercial license

## 2025 review

Deal activity in Pharmaceuticals & Life Sciences rose from 59 to 74 transactions year-on-year, while total deal value increased by c. 30% to c. USD 53.0 billion. The standout deal was Novartis' USD 12.0 billion acquisition of Avidity Biosciences, an innovator in RNA therapeutics that broadens Novartis' late-stage neuroscience pipeline and enhances its position in addressing genetic neuromuscular diseases. Novartis was the top buyer, having executed eight transactions with a total deal value of USD 27.5 billion.

Biotech accounted for 35% of volume, with Medtech/Lab Equipment at 26% and Clinics/Healthcare, Pharma, and other segments consolidated at 39%. Cross-border activity showed 33 inbound deals and 28 Swiss outbound moves, while domestic Swiss transactions reached eight and foreign-to-foreign activity involving Swiss selling parties stood at five.

For more information  
please contact:


**Deborah Lancaster**

Partner, Deal Advisory,  
Life Sciences Strategy  
+41 58 249 78 77  
deborah.lancaster@kpmg.com


**Camal Handor**

Director, Deal Advisory,  
Life Sciences Strategy  
+41 58 249 27 06  
camal.handor@kpmg.com

## 2026 outlook

The impending loss of exclusivity for Ocrevus may prompt Roche to accelerate M&A activity, while improving market conditions could enable a return of Swiss biotech IPOs, reinforcing Switzerland's position at the center of Europe's next deal cycle as a defensive yet growth-oriented life sciences hub with strong innovation and global acquirers.

# Power & Utilities



Deal count

33

Deal value in USD bn

3.5

## Top 3 Swiss Power & Utilities deals 2025

1	2	3
<b>Target</b>	<b>Middle River Power</b>	<b>PowerTransitions LLC</b>
Announced date	Mar 2025	Jun 2025
Stake	100%	100%
Target country	USA	USA
Bidder	Partners Group Holding AG	Partners Group Holding AG
Bidder country	Switzerland	Switzerland
Seller	Avenue Capital Group LLC	EnCap Investments LP
Seller country	USA	USA
Value USD m	2,200	450
		363

## 2025 review

Deal activity in Power & Utilities remained steady at 33 year-on-year, while total deal value increased slightly to c. USD 3.5 billion. Value concentration was pronounced, with Partners Group leading two of the top three transactions, including the USD 2.2 billion acquisition of U.S.-based Middle River Power.

Swiss buyers pursuing foreign targets dominated cross-border activity with 21 deals, complemented by 10 foreign-to-foreign transactions involving groups with Swiss presence and two domestic Swiss deals.

For more information  
please contact:



**Simon Laval**  
Partner, Deal Advisory,  
Valuation/Financial Modelling  
+41 58 249 46 30  
slaval@kpmg.com



**Reto Ringli**  
Director, Deal Advisory,  
Mergers & Acquisitions  
+41 58 249 52 81  
rringli@kpmg.com

## 2026 outlook

We see a clear appetite among Swiss and foreign players for flexibility assets located in the main Western European markets. We expect this trend to continue in 2026. Deal activity is anticipated to remain steady, with continued emphasis on the shift to renewables (and required flexibility assets), along with electrification, supported by smart grids and increased use of technology.

# Private Equity



Deal count  
**142**

Deal value in USD bn  
**46.2**

## Breakdown by subindustry

% of deals, by number

19% Industrial Markets  
16% Pharmaceuticals & Life Sciences  
16% Technology, Media & Telecommunications  
10% Power & Utilities  
6% Consumer Markets  
6% Financial Services  
1% Chemicals  
1% Commodities  
25% Other Industries

## Top 3 Swiss Private Equity deals 2025

1	2	3	
<b>Target</b>	<b>Techem GmbH</b>	<b>ABB Ltd</b> (Robotics division)	<b>89Bio Inc</b>
Announced date	Jul 2025	Oct 2025	Sep 2025
Stake	100%	100%	100%
Target country	Germany	Switzerland	USA
Bidder	Consortium led by Partners Group Holding AG	SoftBank Group Corp	Roche Holding AG
Bidder country	Switzerland	Japan	Switzerland
Seller	Caisse de Depot et Placement du Quebec; Ontario Teachers Pension Plan; Partners Group Holding AG	ABB Ltd	Longitude Capital Management Co LLC; RA Capital Management LP
Seller country	Canada; Canada; Switzerland	Switzerland	USA; USA
Value USD m	<b>7,824</b>	5,375	3,677

## 2025 review

The Private Equity sector remained rather defensive, however, it still experienced some growth, with transactions increasing from 122 to 142 and total value remaining steady at around USD 46.2 billion between 2024 and 2025. Key segments driving this activity included Industrial Markets, Pharmaceuticals & Life Sciences, and TMT. Cross-border deals were significant, with 56 outbound transactions from Switzerland and 48 inbound acquisitions, while foreign-to-foreign transactions with Swiss sellers totaled 33. Purely domestic Swiss activity remained low at five deals.

A significant transaction involved the acquisition of Techem Group by a consortium involving Partners Group for USD 7.8 billion. Other notable deals by value included ABB's divestiture of its robotics division to SoftBank for an enterprise value of USD 5.4 billion and Roche's acquisition of 89Bio Inc., a clinical-stage biopharmaceutical company.

For more information  
please contact:



**Timo Knak**

Partner, Deal Advisory,  
Head Deal Advisory and  
Head of Mergers & Acquisitions  
+41 58 249 42 04  
tknak@kpmg.com



**Hannes Kurz**

Director, Deal Advisory,  
Diligence Services  
+41 58 249 63 27  
hkurz@kpmg.com

## 2026 outlook

In 2026, Swiss Private Equity M&A will likely continue to be selective, but we again expect a slight increase in deal activity given the exit backlog, completed portfolio work, and the significant amounts of dry powder. It remains to be seen how slower economic growth, potential valuation discrepancies, and financing hurdles will limit momentum. Firms will continue to use structured solutions like continuation funds or partial exits to navigate challenges in traditional exits.

# Real Estate



## 2025 review

After an already strong 2024, indirect Real Estate investments experienced another year of very impressive performance and new all-time highs with YTD-returns (as of end of December 2025) of 23.3% and 10.6% for listed real estate companies and funds respectively, reflecting the 0% interest rate environment and a healthy spread to fixed income markets.

On the direct Real Estate market, the upswing observed in the second half of 2024 gained further momentum, leading to a strong 2025 with capital increases of over CHF 8.0 billion. Albeit a significant portion of capital was used for internal transfer of assets from insurance balance sheets to their third-party investment products, the increased liquidity in the market led to rising transaction prices, in particular for residential properties that continue to be in short supply.

Construction activity remained relatively low, hampered by increased regulations and delays due to bureaucracy and extensive possibilities of objection.

The merger of Baloise and Helvetia creates another large player in the Real Estate investment market and leads to further consolidation in the funds segment.

[For more information  
please contact:](#)



**Beat Seger**  
Partner, Deal Advisory,  
Real Estate  
+41 58 249 29 46  
bseger@kpmg.com



**Eric Delé**  
Director, Deal Advisory,  
Real Estate  
+41 58 249 59 40  
edele@kpmg.com

## 2026 outlook

Market activity and investment pressure remain high due to a lack of good alternatives to Real Estate. Price dynamics are expected to slow down to more moderate levels, the main reasons being already high price levels for residential properties, lower rental income increase prospects and financing topics with regard to Basel III. For commercial properties, location, object quality, and sustainability aspects continue to be essential differentiation factors.

However, regulatory risks are influencing the market, as political pressure to fight increasing housing costs (due to a shortage of supply combined with continued high immigration) is fueling discussions about tightening of existing legislations (e.g., Lex Koller) and the introduction of new restrictions (e.g., "Rent Cap" in the canton of Zurich). Declining investment and renovation activity may be the consequence, if these propositions are accepted.

A slight upswing in construction activity is anticipated due to a stabilization of construction costs (albeit at a high level) and expected pull-forward effects due to the abolition of the imputed rental value in 2028 (earliest possible).

# Technology, Media & Telecommunications



Deal count

84

Deal value in USD bn

9.8

## Breakdown by subindustry

% of deals, by number

58% Software

15% Hardware &amp; Electronics

12% Media/Internet

8% IT Services

6% Telecoms

## Top 3 Swiss TMT deals 2025

1	2	3
<b>Target</b>	<b>Global Blue Group Holding AG</b>	<b>u-blox Holding AG</b>
Announced date	Feb 2025	Aug 2025
Stake	100%	100%
Target country	Switzerland	Switzerland
Bidder	Shift4 Payments Inc	Advent International LP
Bidder country	USA	USA
Seller	Public tender offer	Public tender offer
Seller country		
Value USD m	<b>2,905</b>	1,328
		1,254

\* Value equals newly issued shares (incl. exercised overallotment) multiplied by the issue price. The implied market capitalization of SMG at the IPO issue price is USD 5.7bn

## 2025 review

TMT deal volume increased (84 transactions in 2025 vs. 75 transactions last year), making TMT the most active industry sector in 2025 (17% of total number of deals). Total deal value decreased by 62% to USD 9.8 billion. The decline primarily reflects the absence of TelCo mega deals, which had driven an unusually high USD 25.8 billion in 2024 through the Sunrise IPO and Swisscom's acquisition of Vodafone Italy. Excluding these two mega deals, TMT deal value in 2025 was up 37% compared to last year.

The largest TMT deals of the year include the acquisition of payment technology provider Global Blue Group Holding AG by Shift4 Payments Inc. (USD 2.9 billion), the public acquisition of positioning and wireless communication technology firm u-blox by Advent (USD 1.3 billion), and the USD 1.3 billion IPO of 22.3% of shares of online marketplace operator Swiss Marketplace Group (SMG). Besides these transactions, many smaller deals took place, for instance in cybersecurity software and services and digital infrastructure.

For more information  
please contact:


**Florian Bornhauser**

Director, Deal Advisory,  
Head of Strategy Group  
Switzerland  
+41 58 249 79 35  
fbornhauser@kpmg.com


**Urs Meier**

Director, Deal Advisory,  
Diligence Services  
+41 58 249 62 70  
umeier@kpmg.com

## 2026 outlook

We expect 2026 to see sustained strong M&A activity in the TMT sector, driven primarily by continued development and adaptation of sector-specific AI applications, build-out of digital infrastructure (e.g., data centers), consolidation in cybersecurity, as well as continued convergence of tech and other, traditional sectors of the economy.

# Credentials

## Clarity on Mergers & Acquisitions

The Swiss M&A landscape:  
recap and outlook

# We thank all our clients for their trust

## MIGROS

### Migros Group

#### KPMG Deal Advisory

supported the Migros Group with separation planning and execution in the context of a strategic portfolio transformation of Melectronics, SportX, BikeWorld, Micasa, OBI, Do It + Garden, Hotelplan, and Mibelle

2024–2025

## ASKCHEMICALS

### ASK Metallurgy GmbH

#### KPMG Deal Advisory

provided buy-side support and SPA advice to Blitz 24-91 GmbH in their acquisition of ASK Metallurgy GmbH

January 2025

## ACTEMIUM

### Actemium Schweiz AG

#### KPMG Deal Advisory

provided financial and tax due diligence support to Actemium Schweiz AG, part of VINCI Energies, in their acquisition of Robo-Mat AG

January 2025

## datacolor

### Datacolor

#### KPMG Deal Advisory

provided financial and tax due diligence support to Datacolor in their acquisition of Techkom GmbH

January 2025

## EOS HOLDING

### EOS NER SA

#### KPMG Deal Advisory

performed a purchase price allocation for EOS NER SA in the context of their acquisition of a solar park in Portugal

January 2025

## ITAB

### ITAB

#### KPMG Deal Advisory

provided financial due diligence support to ITAB in connection with their acquisition of Financière HMY

January 2025



### Affidea SA

#### KPMG Deal Advisory

provided Affidea SA with financial, tax, and pension due diligence and accounting advisory services in connection with their acquisition of Institut für histologische und zytologische Diagnostik AG Aarau

February 2025



### ECM Equity Capital Management GmbH

#### KPMG Deal Advisory

acted as sole M&A lead advisor and provided financial and tax vendor assistance to funds managed by ECM on the divestment of Apostroph Group to TransPerfect

February 2025



### Migros Group

#### KPMG Deal Advisory

provided separation vendor assistance to the Migros Group and the Hotelplan Group in the context of the Hotelplan Group's sale in two parts (Interhome and Hotelplan), including separation analysis and planning

February 2025



### RCP Group GmbH

#### KPMG Deal Advisory

acted as sole M&A lead advisor and provided financial vendor assistance services to RCP Invest on the divestment of Axicom to Trilantic Europe

February 2025



### Swiss Life Holding AG

#### KPMG Deal Advisory

provided financial and tax due diligence services to Swiss Life Holding AG for the acquisition of 100% Zwei Wealth Experts AG

February 2025



### TK Elevator

#### KPMG Deal Advisory

supported TK Elevator in Germany, Switzerland and Saudi Arabia with pre-signing business planning services, negotiation support, as well as post-signing execution support on its strategic joint venture with Alat

February 2025



### Crédit Agricole next bank (Suisse) SA

#### KPMG Deal Advisory

acted as M&A advisor to Crédit Agricole next bank (Suisse) SA and provided comprehensive due diligence services in relation to the acquisition of a minority stake in a digital FX broker

March 2025



### ECM Equity Capital Management GmbH

#### KPMG Deal Advisory

acted as sole M&A lead advisor and provided financial, commercial, and tax vendor assistance to funds managed by ECM on their divestment of Uroviva Group to Affidea

March 2025



### EOS NER SA

#### KPMG Deal Advisory

performed a purchase price allocation for EOS NER SA in the context of their acquisition of a solar park in Spain

March 2025



## J. Safra Sarasin

### J. Safra Sarasin Group

#### KPMG Deal Advisory

provided financial, tax, regulatory, and compliance due diligence across various jurisdictions, as well as technical valuation services to J. Safra Sarasin Group on the acquisition of 70% of Saxo Bank A/S

March 2025

## HEMRO X XENIA

### HEMRO Group

#### KPMG Deal Advisory

acted as M&A lead advisor and provided legal services to HEMRO Group on the acquisition of Xenia Espresso GmbH

May 2025

## FROMM

### Fromm Holding AG

#### KPMG Deal Advisory

acted as sole M&A lead advisor and provided buy-side due diligence services to Fromm Holding AG on the acquisition of Maillis Metals Solutions from H.I.G

June 2025

## Marubeni

### Marubeni Corporation

#### KPMG Deal Advisory

provided Marubeni Corporation with buy-side financial due diligence services in connection with their equity investment in Gearbulk Holding AG

June 2025

## HELVETICA CAPITAL

### Helvetica Capital AG

#### KPMG Deal Advisory

provided financial and tax due diligence, as well as tax structuring support to Helvetica Capital AG in their acquisition of Statron AG

July 2025

## intershop

### Intershop

#### KPMG Deal Advisory

supported Intershop with the project planning and execution of an internal legal entity merger under FusG

July 2025



### STMicroelectronics

#### KPMG Deal Advisory

provided financial due diligence, purchase price allocation, and tax structuring support to STMicroelectronics in their acquisition of NXP Semiconductors' MEMS sensors business

July 2025

## +GF+

### Georg Fischer AG

#### KPMG Deal Advisory

provided financial vendor assistance support to Georg Fischer AG on the divestment of their GF Casting Solutions division to Nemak S.A.B. de C.V.

August 2025

## Nestlé Health Science

### Nestlé Health Science SA

#### KPMG Deal Advisory

acted as sole M&A lead advisor to Nestlé Health Science SA on the sale of its dietetics firm PronoKal to DUBAG Group

August 2025

**SEAL SQ Corp.**

KPMG Deal Advisory

provided financial, tax, and pensions due diligence support to SEAL SQ Corp. in connection with their acquisition of IC'Alps SAS

August 2025

**Swiss Cardio Technologies AG**

KPMG Deal Advisory

acted as sole M&A lead advisor to the shareholders of Swiss Cardio Technologies AG on the divestment to Abacus Medicine Group

August 2025

**TecMed AG**

KPMG Deal Advisory

acted as sole M&A lead advisor and provided tax due diligence services to TecMed AG on the acquisition of Ypsomed's diabetes care business

August 2025

**ARCHIMED****ARCHIMED**

KPMG Deal Advisory

provided financial and tax due diligence support to ARCHIMED in their acquisition of a majority stake in ExcellGene SA and Magellan Biologics & Consulting

September 2025

**Migros Fachmarkt AG**

KPMG Deal Advisory

acted as sole M&A lead advisor and provided financial vendor assistance and separation services to Migros Fachmarkt AG on the divestment of its furniture retail business Micasa to its management and investors

September 2025

**The SPAR Group Ltd (South Africa)**

KPMG Deal Advisory

provided financial, tax, legal, and pensions vendor assistance support to The SPAR Group Ltd (South Africa) in its divestiture of Spar Switzerland

September 2025

**Zwahlen et Mayr S.A.**

KPMG Deal Advisory

provided financial and tax vendor assistance support to Zwahlen et Mayr S.A. in connection with the envisaged disposal by Cimolai S.p.A of SITINDUSTRIE Suisse

September 2025

**21Shares AG**

KPMG Deal Advisory

provided financial vendor assistance services to 21Shares AG on their sale to FalconX

October 2025

**Fr. Sauter AG**

KPMG Deal Advisory

provided financial, tax, and commercial due diligence support to Fr. Sauter AG in connection with their acquisition of a majority stake in M2B2 Holding S.r.l. and its subsidiaries Proget Impianti S.r.l., Erisist S.r.l. and Eurosicurezza S.r.l.

November 2025



### Tecan Group

#### KPMG Deal Advisory

supported Tecan Group with financial due diligence in their acquisition of Wako Automation assets

December 2025



### Bystronic AG

#### KPMG Deal Advisory

acted as sole M&A lead advisor and provided financial due diligence, tax, separation, and pension services to Bystronic on the acquisition of Coherent's tools for materials processing business

Pending



# Methodology

**This study is based on the Mergermarket and KPMG databases, focusing on deals announced in 2025 but also providing historical data drawn from previous editions of Clarity on Mergers & Acquisitions (formerly M&A Yearbook).**

The consideration of individual transactions and their allocation to specific industry segments are based on our judgment and are thus subjective. We have not been able to extensively verify all data and cannot be held responsible for the absolute accuracy and completeness thereof. Analysis of different data sources and data sets may yield deviating results. Historical data may differ from earlier editions of this Clarity on Mergers & Acquisitions as databases are updated retroactively for lapsed deals or for transactions that were not made public at that given time; we have also aligned some of the selection parameters and industry segmentation more closely to those applied by the above-mentioned databases, which can also lead to differences in historical data representation. The following notes pertain to data contained in this publication.

[www.kpmg.ch/ma](http://www.kpmg.ch/ma)

1

Deals are included where the deal value is equal to or greater than the equivalent of USD 7 million.

2

Value data provided in the various charts represent the aggregate value of the deals for which a value was stated. Please note that values are disclosed for approximately 20 percent of all deals.

3

Where no deal value was disclosed, deals are included if the turnover of the target is equal to or greater than the equivalent of USD 14 million. In cases where sales figures were not disclosed, we approximated the target's turnover based on factors such as the number of employees or any other publicly available size indicators.

4

Deals are included where a stake of 30 percent or more has been acquired in the target. If the stake acquired is less than 30 percent, the deal is included if the value of the stake acquired is equal to or exceeds the equivalent of USD 140 million.

5

Deals are included in their respective industry sector based on the industry of the target's business.

6

All deals included have been announced but may not necessarily have closed.

7

Activities excluded from the data include restructurings where ultimate shareholders' interests are not affected.

**Articles may only be republished by written permission of the publisher and quoting the source "KPMG's Clarity on Mergers & Acquisitions".**

The views and opinions expressed herein are those of the author and do not necessarily represent the views and opinions of the publisher.

The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. If you would like to know more about how KPMG AG processes personal data, please read our **Privacy Policy**, which you can find on our homepage at [www.kpmg.ch](http://www.kpmg.ch)

©2026 KPMG AG, a Swiss corporation, is a group company of KPMG Holding LLP, which is a member of the KPMG global organization of independent firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.